New cell therapy takes on Drug-Resistant melanoma

NCT ID NCT06708455

First seen Apr 04, 2026 · Last updated May 02, 2026 · Updated 2 times

Summary

This phase 2 trial tests a new cell therapy called RAPA-201 for people with advanced melanoma that has spread or come back after standard immunotherapy. The treatment uses a patient's own immune cells that are specially trained to resist a drug called rapamycin, aiming to boost their cancer-fighting power. About 65 adults with stage IIIc or IV melanoma that no longer responds to PD-(L)1 inhibitors will receive this therapy to see if it can shrink tumors and improve survival.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • Hackensack University Medical Center

    Hackensack, New Jersey, 07601, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.